Understanding why some Kaposi's sarcoma patients don't respond to treatment
Pathogenesis of the cART unresponsive Kaposi’s sarcoma tumor niche
This study is looking into why some people with Kaposi's sarcoma, a cancer linked to AIDS, don't get better with standard HIV treatments, by examining tissue samples to understand what makes their tumors different and how their immune systems respond.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10669148 on NIH RePORTER |
What this research studies
This research investigates the reasons why certain patients with Kaposi's sarcoma, a cancer associated with AIDS, do not respond to combined anti-retroviral therapy (cART). By analyzing tissue samples from patients who have undergone treatment, the study aims to identify specific tumor characteristics and immune responses that differentiate those who progress with the disease from those who achieve remission. The research utilizes a collection of pre-treatment tissue samples to explore the underlying mechanisms of treatment resistance, focusing on immune cell behavior and tumor biology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Kaposi's sarcoma who are also HIV positive and have undergone or are undergoing cART.
Not a fit: Patients with Kaposi's sarcoma who are not HIV positive or those who have not received cART may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with Kaposi's sarcoma, potentially increasing remission rates.
How similar studies have performed: Previous research has shown that understanding tumor biology and immune responses can lead to breakthroughs in cancer treatment, suggesting potential success for this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Mcgrath, Michael Shannon — University of California, San Francisco
- Study coordinator: Mcgrath, Michael Shannon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.